DaVita Income from Continuous Operations 2010-2024 | DVA
DaVita annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- DaVita income from continuous operations for the quarter ending September 30, 2024 was $0.296B, a 4.4% decline year-over-year.
- DaVita income from continuous operations for the twelve months ending September 30, 2024 was $1.132B, a 34.84% increase year-over-year.
- DaVita annual income from continuous operations for 2023 was $0.957B, a 24.58% increase from 2022.
- DaVita annual income from continuous operations for 2022 was $0.768B, a 36.61% decline from 2021.
- DaVita annual income from continuous operations for 2021 was $1.212B, a 20.65% increase from 2020.
DaVita Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$957 |
| 2022 |
$768 |
| 2021 |
$1,212 |
| 2020 |
$1,004 |
| 2019 |
$916 |
| 2018 |
$790 |
| 2017 |
$1,076 |
| 2016 |
$1,191 |
| 2015 |
$481 |
| 2014 |
$863 |
| 2013 |
$744 |
| 2012 |
$641 |
| 2011 |
$591 |
| 2010 |
$482 |
| 2009 |
$479 |
DaVita Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$296 |
| 2024-06-30 |
$300 |
| 2024-03-31 |
$306 |
| 2023-12-31 |
$231 |
| 2023-09-30 |
$309 |
| 2023-06-30 |
$246 |
| 2023-03-31 |
$171 |
| 2022-12-31 |
$113 |
| 2022-09-30 |
$165 |
| 2022-06-30 |
$285 |
| 2022-03-31 |
$206 |
| 2021-12-31 |
$249 |
| 2021-09-30 |
$320 |
| 2021-06-30 |
$351 |
| 2021-03-31 |
$292 |
| 2020-12-31 |
$254 |
| 2020-09-30 |
$218 |
| 2020-06-30 |
$255 |
| 2020-03-31 |
$278 |
| 2019-12-31 |
$300 |
| 2019-09-30 |
$209 |
| 2019-06-30 |
$248 |
| 2019-03-31 |
$159 |
| 2018-12-31 |
$207 |
| 2018-09-30 |
$115 |
| 2018-06-30 |
$237 |
| 2018-03-31 |
$231 |
| 2017-12-31 |
$197 |
| 2017-09-30 |
$199 |
| 2017-06-30 |
$186 |
| 2017-03-31 |
$494 |
| 2016-12-31 |
$347 |
| 2016-09-30 |
$612 |
| 2016-06-30 |
$95 |
| 2016-03-31 |
$138 |
| 2015-12-31 |
$88 |
| 2015-09-30 |
$261 |
| 2015-06-30 |
$208 |
| 2015-03-31 |
$-76 |
| 2014-12-31 |
$250 |
| 2014-09-30 |
$220 |
| 2014-06-30 |
$181 |
| 2014-03-31 |
$212 |
| 2013-12-31 |
$244 |
| 2013-09-30 |
$170 |
| 2013-06-30 |
$283 |
| 2013-03-31 |
$46 |
| 2012-12-31 |
$184 |
| 2012-09-30 |
$173 |
| 2012-06-30 |
$120 |
| 2012-03-31 |
$165 |
| 2011-12-31 |
$192 |
| 2011-09-30 |
$164 |
| 2011-06-30 |
$120 |
| 2011-03-31 |
$115 |
| 2010-12-31 |
$90 |
| 2010-09-30 |
$143 |
| 2010-06-30 |
$124 |
| 2010-03-31 |
$125 |
| 2009-12-31 |
$125 |
| 2009-09-30 |
$126 |
| 2009-06-30 |
$120 |
| 2009-03-31 |
$108 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$12.098B |
$12.140B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
